Revenue, 2025

USD 5.3 Billion

Forecast, 2035

USD 10.23 Billion

CAGR, 2026-2035

6.8%

Report Coverage

Global

Pulmonary Function Testing Systems Market Trends for 2026

The global pulmonary function testing systems market size was estimated at USD 5.3 billion in 2025 and is predicted to increase from USD 5.66 billion in 2026 to approximately USD 10.23 billion by 2035, expanding at a CAGR of 6.8% from 2026 to 2035. The worldwide massive rise in environmental pollution, rising smoking rates & geriatric population are highly susceptible to different respiratory diseases like COPD, asthma, etc. For these cases, leading companies are putting efforts into the development of portable, handheld devices, coupled with AI solutions & home care approaches.

Key Takeaways

• Pulmonary function testing systems market to crossed USD 5.66 billion by 2026.
• Market projected at USD 10.23 billion by 2035.
• CAGR of 6.8% expected in between 2026 to 2035.
• North America accounted for 40% share of the market in 2025.
• Asia Pacific held 20% share in 2025 & is expected to grow at 7.00% CAGR during the forecast period.
• By type, the spirometers segment dominated with 45% share of the market in 2025.
• By type, the handheld spirometers sub-segment is expected to grow fastest at 7.20% CAGR in the upcoming years.
• By end-user, the hospitals segment led with 50% revenue share of the market in 2025.
• By end-user, the home care segment captured 15% share in 2025& is expected to witness rapid growth at 8.2% CAGR in the studied years.
• By application, the chronic obstructive pulmonary disease (COPD) segment held 35% share of the market in 2025.
• By application, the asthma segment accounted for 30% share in 2025 & is expected to grow at 7.5% CAGR during 2026-2035.

What are the Growth Factors of Pulmonary Function Testing Systems?

The global pulmonary function testing systems market covers non-invasive diagnostic tools to record how well lungs take in & exhale air, and how efficiently they transfer oxygen to the blood. The market progression is propelled by the growing incidence of diverse chronic respiratory diseases, rise in geriatric population, broader air pollution, & immersive, fastest adoption of portable, AI-powered diagnostic systems for prior, extensive lung function evaluation. 

How is AI Supporting the Expansion of the Pulmonary Function Testing Systems Market?

Primarily, the use of AI assists in ensuring tests are operated appropriately, with immediate identification of technical flaws, which offer instant feedback to patients & technicians. However, eventual advancements in AI algorithms, specifically deep learning is fostering the analysis of PFT results to categorize patterns. Due to the automated, continuous interpretations, AI lowers the diversity & subjectivity linked with manual interpretation of PFT results.

Trends & Future Outlook of the Pulmonary Function Testing Systems Market

Bolstering Portability & Home Testing

Gradually, the firms are stepping toward compact, portable PFT systems to employ outside hospitals, like point-of-care, primary care, & home settings.

Spurring Digital Integration & Connectivity

Incorporation of modern systems features cloud connectivity, enabling instant data analysis, remote monitoring, & perfect electronic health record (EHR) integration.

Promoting Innovative Techniques

The globe is pushing the Forced Oscillation Technique (FOT/Resistive Oscillometry) technique to measure lung function without the need for forced breathing, which makes it favourable for children & patients with severe, restrictive, or obstructed lung diseases.

Quick Facts Table

Segmental Analysis

Type Insights

The Spirometers Segment Led the Market in 2025

The spirometers segment held 45% share of the pulmonary function testing systems market in 2025. Dominance is driven by its wider adoption in the diagnosis of issues, including asthma & COPD, with assessment of pre-operative risk, & screening for occupational lung diseases. The trend is exploring the use of ultrasonic and Venturi-based flow sensors, strict ATS/ERS 2022 standards, and leveraging Global Lung Function Initiative (GLI) reference equations.

The handheld spirometers sub-segment is predicted to expand at 7.20% CAGR. Accelerating demand for home-based monitoring, & consistent technological breakthroughs, such as Bluetooth-connected, AI-enhanced, & user-friendly devices, are fueling the overall progression.

 The peak flow meters segment held the second-largest share of 20% in 2025, due to the increasing prevalence of asthma, which enables patients to monitor their asthma daily, understanding early signs of worsening symptoms, especially for those who struggle to recognize exacerbations.

The gas analyzers segment captured 15% share of the pulmonary function testing systems market. This type has extensive application in both diagnostic & research applications for pulmonary health. The market is executing Non-Dispersive Infrared (NDIR) technology for multi-gas analysis & ultrasonic flow sensors for precise, maintenance-free, & real-time study of gas exchange (DLCO) & lung volumes.

The oximeters segment held 10% share in 205, due to the surging adoption for monitoring oxygen saturation, specifically in home care. Alongside, the globe is widely using multi-wavelength technology to capture more than just oxygen saturation.

End-User Insights

The Hospitals Segment Dominated the Market in 2025

In 2025, the hospitals segment was dominant with 50% share of the market. As per the survey, there were approximately 400 million people with COPD, & 260 million people have asthma issues, which has propelled the expansion of hospitals. Hospitals are providing assessment of respiratory risk before surgeries, often initiating from surgical areas.

The clinics segment held 25% share of the pulmonary function testing systems market. They are increasingly employing PFTs to study risks for patients undergoing thoracic or upper abdominal surgeries. Also, implementing Cardiopulmonary Exercise Testing (CPET) in the analysis of exercise-induced challenges & mortality risk in COPD patients.

Moreover, the home care segment held 15% share in 2025 & is estimated to expand at 8.2% CAGR. Catalysts are a growth in demand for remote patient monitoring, lowering hospital visits, improving affordability, & the need for daily symptom tracking. Leading companies are fostering miniaturized, user-friendly, & accurate handheld devices for precise tests at home.

The ambulatory surgical centers (ASCs) segment captured 10% share, due to the 30-50% reduction in procedure spending compared to hospitals, with emphasis on PFTs on-site that simplifies the patient experience, avoids hospital risks, & supports handling preoperative evaluation expenditures.

Application Insights

The Chronic Obstructive Pulmonary Disease (COPD) Segment Led the Market in 2025

In 2025, the chronic obstructive pulmonary disease (COPD) segment dominated with 35% share of the pulmonary function testing systems market. A substantial rise in environmental pollution, smoking rates, & notably rising COPD cases are fueling the demand for advanced testing approaches. Ongoing developments are embracing forced oscillation techniques, advanced imaging, & AI to foster diagnosis.

The asthma segment captured 30% share in 2025 & is predicted to expand at 7.5% CAGR. Elevating awareness is focusing on airway inflammation, reversible airflow obstruction, & Small Airway Dysfunction (SAD). Apart from home care, the market rolled out FeNO as a beneficial marker of eosinophilic airway inflammation & assists in evaluating treatment responsiveness, mainly in children.

The cystic fibrosis segment held 15% share of the pulmonary function testing systems market, due to the escalating newborn screening for cystic fibrosis, which ensures earlier diagnosis, & further demand for accurate diagnostic tests, including sweat tests & PFTs.

Regional Insights

How did North America Dominate the Market in 2025?

North America led with 40% share in 2025, due to the higher healthcare expenditure & possession of robust medical infrastructure. The regional systems are moving towards portable, handheld, & wireless-enabled PFT systems. Novelty comprises Canada's foremost mobile Lung Health Check PFT unit in Alberta to elevate access to screening in rural, remote, & Indigenous communities.

U.S. Market Trends

The pulmonary function testing systems market in the U.S. captured a major share of 35% & is actively enforcing calibration-free spirometers with AI quality checks & broader adoption of TeleSpirometry in VA clinics for COPD management.

For instance,

• In January 2026, coVita LLC & Allergy Partners joined to facilitate FeNO testing with the NObreath device, & raise patient access in asthma diagnosis & management.

Expedited Urbanization & Strong Incentives are Driving the Asia Pacific

Asia Pacific held 20% of the market share and is anticipated to witness rapid growth at 7.00%, due to the surging ageing population, coupled with faster urbanization, which speeds up cases of various lung-related disorders & pushes the need for advanced systems. In addition, the APAC is boosting innovation in technologies, like compact, AI-assisted, & portable spirometers, prominently in primary care & remote areas.

China Market Trends

China’s pulmonary function testing systems market is rapidly growing at 8.0% CAGR with immersive government efforts, including the Happy Breathing Program, which accelerates the active deployment of spirometers to community healthcare centers to allow for early screening & management of chronic respiratory diseases.

Emerging Policies & Extensive Advancements are Fueling Europe

In 2025, Europe held 30% share of the market, which is estimated to expand at a lucrative CAGR of 6.00% in the coming era. This has been impelling due to the enforcement of the latest European Respiratory Society (ERS)/American Thoracic Society (ATS) standards for spirometry, lung volumes, & diffusing capacity, which focuses on strict quality control & automated grading for accurate testing.

For instance,

• In February 2024, Jiva.ai & Aevice Health collaborated on a co-innovation programme funded by Innovate UK & Enterprise Singapore to develop a state-of-the-art medical AI to estimate asthma exacerbations.

UK Market Trends

Whereas, the UK’s pulmonary function testing systems market is anticipated to grow at 6.50% CAGR, with rigorous emphasis on the detection of issues early to prevent prospective risks. Also, the UK firms are leveraging cloud-connected PFT analytics, automated body-box operations, & handheld devices to offer clinical-grade diagnostics & also support the NHS's shift toward community-based testing.

Key Players' Offerings in the Pulmonary Function Testing Systems Market

SWOT Analysis

Strengths

• The use of PFTs gives a painless & safe solution, enabling frequent, repetitive monitoring of lung health without radiation risk.
• Advanced systems can offer evaluation of airflow, total air capacity, & oxygen transfer capability.

Weaknesses

• Sometimes, systems can show short expiration times, hesitation during the beginning of the test, & air leaks around the mouthpiece.
• Developing test results can be uneven due to recent smoking, heavy meals, caffeinated drinks, or medication usage.

Opportunities

• The global healthcare system will execute portable, hand-held devices to allow point-of-care (POC) testing.
• Leaders will roll out AI algorithms to lower operator dependence, enhance the standardization of tests, & detect early alterations in lung function.

Threats

• Specifically, failure to perform adequate PFTs or act on abnormal outputs can result in Occupational Safety and Health Administration (OSHA) violations & major legal liability.
•  PFT equipment can serve as a reservoir for pathogens, which need stringent disinfection or expensive, single-use, disposable mouthpieces & filters to mitigate the spread of infections among employees.

What are the Key Developments in the Pulmonary Function Testing Systems Market?

• In February 2026, Emirates Health Services (EHS) introduced a novel tool to find respiratory concerns in children at an early stage.
• In February 2026, Zydus Lifesciences Limited launched PEPAIR, India's first cost-effective Oscillating Positive Expiratory Pressure (OPEP) device.
• In February 2025, Visby Medical received 510(k) clearance & was granted a CLIA waiver from the US FDA for its Visby Medical Respiratory Health Test.

Segments Covered in the Report

By Type

• Spirometers
  • Handheld Spirometers
  • Desktop Spirometers
• Peak Flow Meters
• Gas Analyzers
• Oximeters
• Others

By End-User

• Hospitals
• Clinics
• Home Care
• Ambulatory Surgical Centers (ASCs)

By Application

• Chronic Obstructive Pulmonary Disease (COPD)
• Asthma
• Cystic Fibrosis
• Other Respiratory Diseases

By Region

• North America
  • U.S.
  • Canada 
  • Mexico 
  • Rest of North America
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Europe 
  • Western Europe 
    • Germany 
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal 
    • Belgium
    • Ireland
    • UK 
    • Iceland 
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe 
    • Austria
    • Russia & Belarus 
    • Türkiye
    • Albania 
    • Rest of Eastern Europe 
• Asia Pacific
  • China 
  • Taiwan
  • India 
  • Japan 
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea 
  • Rest of APAC 
• MEA 
  • GCC Countries
    • Saudi Arabia 
    • United Arab Emirates (UAE)
    • Qatar 
    • Kuwait 
    • Oman 
    • Bahrain 
  • South Africa
  • Egypt 
  • Rest of MEA